Moderna (NASDAQ:MRNA – Get Rating) had its price target lowered by investment analysts at Piper Sandler from $348.00 to $214.00 in a report issued on Tuesday, The Fly reports. Piper Sandler’s price objective points to a potential upside of 50.41% from the stock’s previous close.
Several other brokerages have also issued reports on MRNA. SVB Leerink reduced their price target on Moderna from $81.00 to $80.00 and set an “underperform” rating for the company in a report on Friday, March 25th. Redburn Partners upgraded Moderna from a “sell” rating to a “neutral” rating in a report on Tuesday, February 1st. UBS Group initiated coverage on Moderna in a research note on Friday, January 21st. They issued a “neutral” rating and a $221.00 price objective on the stock. Bank of America raised Moderna from an “underperform” rating to a “neutral” rating and raised their price objective for the company from $135.00 to $180.00 in a research note on Friday, January 21st. Finally, Barclays cut their price objective on Moderna from $404.00 to $210.00 in a research note on Friday, February 25th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $236.62.
Shares of NASDAQ:MRNA traded up $6.02 during midday trading on Tuesday, reaching $142.28. The company had a trading volume of 5,958,816 shares, compared to its average volume of 7,738,438. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.56 and a current ratio of 1.77. Moderna has a 1-year low of $119.01 and a 1-year high of $497.49. The firm has a market cap of $56.59 billion, a price-to-earnings ratio of 4.18, a price-to-earnings-growth ratio of 0.78 and a beta of 1.70. The company has a fifty day simple moving average of $155.62 and a two-hundred day simple moving average of $197.72.
In other Moderna news, Director Noubar Afeyan sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 11th. The stock was sold at an average price of $130.74, for a total value of $1,307,400.00. Following the transaction, the director now owns 2,229,673 shares of the company’s stock, valued at $291,507,448.02. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Stephane Bancel sold 9,000 shares of the business’s stock in a transaction on Wednesday, February 16th. The stock was sold at an average price of $147.80, for a total value of $1,330,200.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 288,126 shares of company stock worth $42,846,474. Company insiders own 17.30% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Stokes Family Office LLC increased its holdings in shares of Moderna by 8.2% in the third quarter. Stokes Family Office LLC now owns 1,162 shares of the company’s stock worth $447,000 after acquiring an additional 88 shares in the last quarter. Horizon Investments LLC bought a new stake in shares of Moderna in the third quarter worth about $2,137,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of Moderna in the third quarter worth about $159,563,000. LPL Financial LLC increased its holdings in shares of Moderna by 19.3% in the third quarter. LPL Financial LLC now owns 150,061 shares of the company’s stock worth $57,753,000 after acquiring an additional 24,239 shares in the last quarter. Finally, First Republic Investment Management Inc. increased its holdings in shares of Moderna by 10.9% in the third quarter. First Republic Investment Management Inc. now owns 98,867 shares of the company’s stock worth $38,050,000 after acquiring an additional 9,679 shares in the last quarter. 61.20% of the stock is currently owned by institutional investors.
Moderna Company Profile (Get Rating)
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Beware The Rebound In Home Depot
- Time to Ride These 3 Mid Cap Momentum Plays
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.